Survival trends among Danish patients undergoing coronary angiography for known or suspected ischaemic heart disease: a population based follow up study, 1992–2000

S P Johnsen, J Videbæk, L Pedersen, R Steffensen, R Videbæk, T Niemann, T T Nielsen, H T Sørensen

Objective: To determine, from population based clinical data, changes in the survival of Danish patients examined by coronary angiography for known or suspected ischaemic heart disease (IHD) during the 1990s.

Design: Follow up study.

Setting: The departments of cardiology at Rigshospitalet, Copenhagen University Hospital, and Skejby Hospital, Aarhus University Hospital, Denmark.


Main outcomes measures: Three year survival was compared between cohorts and with that of the general population. Cox proportional hazards regression was used to estimate mortality ratios adjusted for differences in patient characteristics.

Results: Survival improved substantially—for example, adjusted mortality ratio was 0.69 (95% confidence interval (CI) 0.55 to 0.87) when comparing patients from 2000 with patients from 1992. The absolute standardised survival rates after three years of follow up were 87.1% (95% CI 85.4% to 88.8%), 89.9% (95% CI 88.5% to 91.3%), and 91.2% (95% CI 90.3% to 92.1%) among patients examined in 1992, 1996, and 2000, respectively. The improvement was not explained by the improvement in overall survival in the general population during the study period.

Conclusions: The survival of Danish patients with known or suspected IHD appears to have improved substantially during the 1990s.

M ortality from ischaemic heart disease (IHD) has been decreasing for at least two decades in Western Europe, the USA, and Australia.1–4 The decrease has been linked to primary and secondary prevention efforts, as well as to improvements in acute care.5–7 However, long term trends in mortality are hard to interpret, as effects of changes in incidence cannot be separated from changes in survival. Interpretation is further complicated by changes in diagnostic criteria for IHD and in the pattern of IHD presentation among hospitalised patients. Fewer patients now present with severe IHD, in particular myocardial infarction with extensive myocardial damage.8

Research on the prognosis of patients with IHD is most often based on clinical trials or administrative data, such as hospital discharge registries or insurance claims databases.9–13 Both approaches have important limitations. Patients in clinical trials may not be representative of the total patient population; they are typically recruited during a limited time span; and length of follow up tends to be relatively short. Routinely collected administrative data often lack clinical information that can ensure comparability of patient populations over time.

Relatively few studies have examined changes in the survival of patients with IHD in population based data supplemented by clinical information.14–18 Furthermore, few studies have compared trends in survival of patients with IHD with overall survival trends for the general population.19

Our study examined trends in survival rates in a population based sample of Danish patients with known or suspected IHD between 1992 and 2000, taking differences in patient characteristics into account and comparing their survival with survival in the general population.

METHODS

Design and study population

We conducted this follow up study among three cohorts of patients with known or suspected IHD (n = 7025): cohort 1 underwent first time coronary angiography in 1992; cohort 2 in 1996; and cohort 3 in 2000. The procedures took place at two major departments of cardiology (Rigshospitalet, Copenhagen University Hospital, and Skejby Hospital, Aarhus University Hospital). These hospitals provided invasive cardiac services for the population living in Copenhagen and the counties of Frederiksberg, Roskilde, Vestsjælland, Storestrøm, Bornholm, Aarhus, Viborg, and Ringkøbing, with a total of 2.9 million inhabitants (about 55% of the total Danish population). Patients under 18 years were excluded (n = 4). The Danish National Health Service provides tax supported health care for all citizens. It ensures free access to general practitioners, hospitals, and public clinics and refunds a variable proportion of the costs of prescribed drugs.

Abbreviations: CABG, coronary artery bypass grafting; CI, confidence interval; EUROASPIRE, European action on secondary prevention through intervention to reduce events; ICD, International classification of diseases; IHD, ischaemic heart disease; PCI, percutaneous coronary intervention.
Patient characteristics
We obtained the following data from medical records or local clinical databases: age, sex, indication for coronary angiography—that is, acute or semi-acute (patient unstable or waiting time ≤ 7 days)—and angiographic status (no significant stenosis, single vessel disease, double vessel disease, triple vessel disease, or proximal left main coronary artery stenosis). “No significant stenosis” was defined as stenosis occupying less than 50% of the lumen. All data were recorded on standardised forms at the time of coronary angiography and were available as a hard copy or electronically, depending on the year of examination.

Data on cardiovascular and non-cardiovascular co-morbidities at baseline were obtained from the Danish National Registry of Patients. This registry, established in 1977, contains records on 99.4% of discharges from non-psychiatric hospitals in Denmark. The data include civil registry number, dates of admission and discharge, surgical procedures performed, and up to 20 discharge diagnoses coded by medical doctors at discharge until 1993 according to the Danish version of the International classification of diseases, 8th revision (ICD-8) and subsequently according to the national version of ICD-10. Data from the National Registry of Patients were used to calculate a co-morbidity index score for each patient as described by Charlson et al. The Charlson index covers 19 major disease categories, including acute myocardial infarction, congestive heart failure, cerebrovascular disease, and cancer, weighted according to their prognostic impact on patient survival. The index was previously adapted for use with hospital discharge registry data.

We defined three levels of co-morbidity for each patient based on a complete hospital discharge history from all non-psychiatric Danish hospitals for the 10 year period preceding the index date, as follows: 0 co-morbidities (none) for patients with no recorded underlying diseases included in the Charlson index; 1-2 co-morbidities (low); and >2 co-morbidities (high).

Information on coronary revascularisation procedures—that is, percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)—performed in direct connection with the baseline coronary angiography or within one year of follow up was also obtained from the National Registry of Patients.

Data on survival
Records in population based registries can be accurately linked in Denmark through the civil registry number—a unique, permanent personal identification number given to every Danish citizen. We obtained information on survival through record linkage with the Civil Registration System, which has electronic records on all changes in vital status, including change of address, date of emigration, and date of death for the entire Danish population since 1968.

To compare patient survival with survival among the general population, we selected a representative sample of the general population for each of the three patient cohorts. Ten people from the general population were selected for each patient, frequency matched on year of birth and sex.

Statistical analysis
Characteristics of the three cohorts were compared by linear regression for the continuous variables (such as age) and $\chi^2$ tests for the categorical variables.

Follow up began on the date of the first coronary angiography and ended on the date of death, the date of emigration, or after three years, whichever came first.

We used Cox proportional hazards regression to estimate mortality ratios adjusted for prognostic factors—that is, age, sex, indication for coronary angiography, angiographic status, and level of co-morbidity. The 1992 cohort served as the reference for all analyses.

We also carried out analyses with separate Cox models, stratifying by age, sex, indication for angiography, angiographic status, level of co-morbidity, and revascularisation treatment group. We used the likelihood ratio test to evaluate homogeneity.

To take into account any changes in the overall survival of the general population during the study period, we compared the survival of the three samples from the general population after having standardised the 1992 and 1996 samples to the age and sex distribution of the 2000 sample. We then adjusted for the change in overall survival in the comparisons between the three patient cohorts in the Cox models.

Lastly, survival curves for the three cohorts were plotted to compare the absolute survival rates after having standardised the 1992 and 1996 cohorts to the age, sex, indication for angiography, angiographic status, and co-morbidity distribution of the 2000 cohort. We compared the survival curves by log rank tests.

The assumption of proportional hazards in the Cox models was evaluated by graphic assessment. There were indications that the assumption was not fulfilled for the entire follow up period and some caution is therefore warranted when interpreting the risk estimates. We estimated 95% confidence intervals (CIs) for all analyses. Our statistical analyses were done with SAS version 8.00 (SAS Institute Inc, Cary, North Carolina, USA).

RESULTS
Table 1 shows demographic and medical characteristics of each of the three cohorts, totalling 7021 patients. The number of patients undergoing first time coronary angiography increased by a factor of three between 1992 and 2000. Observed trends were a higher mean age, higher proportion of women, more patients with acute indications, more patients with no significant stenoses or single vessel disease, and more patients undergoing a revascularisation procedure in direct connection with the baseline coronary angiography within one year of follow up, and more patients with high co-morbidity index scores (p < 0.001). Furthermore, the median time from coronary angiography to revascularisation dropped dramatically as more patients were revascularised in direct connection with the baseline coronary angiography.

Combining all three cohorts, we identified a total of 792 deaths during follow up. This corresponds to a mortality of 40.6 deaths/1000 person years of risk.

Table 2 provides crude and adjusted mortality ratios during three years of follow up according to the year of first time coronary angiography for known or suspected IHD. No clear changes in mortality over time were seen in the crude analyses. However, after adjusting for covariates, we found a substantial improvement in survival, for example, the adjusted mortality ratio was 0.69 (95% CI 0.55 to 0.87) when comparing patients from 2000 with patients from 1992. Age and angiographic status were the most influential confounding factors.

To evaluate the possibility that improved survival over time among patients with known or suspected IHD was restricted to certain subgroups of patients, we stratified our analyses according to age, sex, angiographic status, level of co-morbidity, and revascularisation treatment group (table 3). Indications of improved survival over time were observed in all strata; however, not all mortality ratios reached significance. Although the mortality ratios varied, there were no significant differences in the stratified analyses.

The improvement in survival of patients with known or suspected IHD during the study period appeared not to be
explained by the improvement in overall survival for the general population during the same period. Thus, the adjusted mortality ratios for the 1996 and 2000 cohorts were 0.88 (95% CI 0.74 to 1.05) and 0.77 (95% CI 0.63 to 0.95), respectively, when we further adjusted for the improvement in overall survival of the general population during the study period.

Figure 1 presents standardised survival functions for patients in the 1992, 1996, and 2000 cohorts. The absolute standardised survival rates after three years of follow up were 87.1% (95% CI 85.4 to 88.8), 89.9% (95% CI 88.5 to 91.3), and 91.2% (95% CI 90.3 to 91.2) for the 1992, 1996, and 2000 cohorts, respectively.

**DISCUSSION**

We found a major improvement in the survival of Danish patients with known or suspected IHD during the 1990s in this population based follow up study. The improvement was found consistently in all subgroups of patients examined, although the improvement did not reach significance in all subgroups. The improvement could not be explained by changes during the study period in the available patient characteristics including age, sex, indication (acute or elective), angiographic status, and Charlson co-morbidity index. Furthermore, the improvement in survival of patients with IHD appeared not to be explained by the improvement in overall survival of the general population during the same period.

The strength of our study is a prospective population based design with complete long term follow up, minimising the risk of selection bias. The availability of detailed individual level clinical data, including angiographic status, level of co-morbidity, and revascularisation during follow up, made it possible to adjust for changes in patient characteristics during the study period. Furthermore, the study included a direct comparison of the improvements in survival between patients with IHD and the general population during the period of observation. This comparison is important, since survival among the general population may have changed because of improvements in the prevention and treatment of diseases other than IHD. These improvements also apply to patients with IHD, who often have coexisting diseases that may eventually cause death. Not taking this into consideration would have led us to overestimate improvements in survival solely related to IHD.

The study was limited by a lack of postangiographic data, including changes in lifestyle factors such as smoking, physical inactivity, and diet, as well as use of cardiovascular drugs. This prevented us from isolating the reasons for improved survival. Furthermore, although we adjusted for a number of differences in patient characteristics, our findings still could have been influenced by undetected differences due to missing data, such as ejection fraction, or due to the use of relatively crude data for some variables, such as level of co-morbidity. However, it should be noted that the validity of some hospital discharge diagnoses, such as acute myocardial infarction, appears to be quite high in the Danish National Registry of Patients.

Our study accords with and extends the findings of a number of other studies on western populations. Together,
they show an encouraging trend in the survival of patients with a hospital discharge diagnosis of IHD during the past two decades.7 10–18 The majority of existing studies have focused on patients with acute myocardial infarction, whereas data on survival trends in patients with stable angina are sparse. Little attention has been paid to the changing pattern of IHD, characterised by relatively more patients with milder forms of IHD. However, the consistency with which the survival improvement has been found in various settings and patient populations indicates that the findings most likely reflect a true and substantial improvement in both short and relative long term survival of patients with IHD in most Western populations.

Determinants of illness outcome should be taken into account23 when considering possible explanations for improved survival. These include patient characteristics and the illness itself, diagnostic tests used to identify the cause and severity of the disease, treatments, quality of care, and level of patient compliance.23 In our study, we controlled for major patient characteristics, such as severity of IHD, and for choice of diagnostic tests as possible explanations for the improved survival; however, treatment, quality of care, and patient compliance may have changed.

Increased use of effective treatments, including aspirin and other antiplatelet drugs, β blockers, angiotensin converting enzyme inhibitors, statins, and coronary revascularisation,

![Table 3](image)

| Table 3 Crude and adjusted MRs stratified by age, sex, angiographic status, level of co-morbidity, and revascularisation treatment group among patients examined with first time coronary angiography for known or suspected ischaemic heart disease in 2000 (1992 is used as reference) |
|---------------------------------|------------------|------------------|------------------|------------------|
| **Crude MR (95% CI)** | **Adjusted MR* (95% CI)** | **Crude MR (95% CI)** | **Adjusted MR* (95% CI)** |
| Age (years) | | | | |
| 19-49 | 0.47 (0.22 to 1.02) | 0.51 (0.22 to 1.18) | 0.58 (0.31 to 1.05) | 0.51 (0.22 to 1.18) |
| 50-69 | 0.82 (0.63 to 1.06) | 0.89 (0.66 to 1.19) | 0.65 (0.52 to 0.82) | 0.67 (0.51 to 0.89) |
| ≥70 | 0.91 (0.62 to 1.34) | 0.91 (0.54 to 1.54) | 0.88 (0.63 to 1.23) | 0.82 (0.49 to 1.35) |
| Sex | | | | |
| Men | 0.94 (0.74 to 1.21) | 0.88 (0.67 to 1.15) | 0.92 (0.75 to 1.13) | 0.70 (0.54 to 0.90) |
| Women | 0.84 (0.56 to 1.26) | 0.74 (0.45 to 1.21) | 0.99 (0.71 to 1.39) | 0.69 (0.44 to 1.08) |
| Indication | | | | |
| Acute | 0.90 (0.50 to 1.62) | 0.81 (0.45 to 1.46) | 0.94 (0.55 to 1.62) | 0.73 (0.42 to 1.26) |
| Elective | 0.84 (0.67 to 1.03) | 0.85 (0.65 to 1.11) | 0.72 (0.59 to 0.89) | 0.66 (0.51 to 0.86) |
| Angiographic status | | | | |
| No significant stenoses | 0.89 (0.42 to 1.38) | 0.72 (0.54 to 1.09) | 1.16 (0.62 to 2.15) | 0.69 (0.36 to 1.34) |
| 1 or 2 VD | 1.20 (0.78 to 1.83) | 0.94 (0.61 to 1.45) | 1.53 (1.04 to 2.24) | 0.87 (0.58 to 1.31) |
| 3 VD or PLM stenosis | 1.25 (0.93 to 1.69) | 0.84 (0.62 to 1.15) | 1.21 (0.92 to 1.54) | 0.63 (0.46 to 0.83) |
| Charlson co-morbidity index | | | | |
| 0 | 0.66 (0.42 to 1.03) | 0.72 (0.63 to 1.09) | 0.61 (0.42 to 0.89) | 0.61 (0.38 to 0.99) |
| 1–2 | 0.87 (0.43 to 1.87) | 0.92 (0.67 to 1.27) | 0.95 (0.75 to 1.20) | 0.70 (0.51 to 0.96) |
| 3+ | 0.85 (0.54 to 1.37) | 0.74 (0.45 to 1.20) | 0.88 (0.65 to 1.24) | 0.68 (0.45 to 1.07) |
| Revascularisation at baseline or within one year of follow up | | | | |
| Yes | 0.98 (0.72 to 1.32) | 0.85 (0.60 to 1.20) | 0.90 (0.70 to 1.18) | 0.61 (0.44 to 0.84) |
| No | 0.79 (0.60 to 1.05) | 0.88 (0.63 to 1.24) | 0.92 (0.73 to 1.16) | 0.87 (0.64 to 1.19) |

*Adjusted for age, sex (except when stratified by sex), indication (acute or elective) (except when stratified by indication), angiographic status (except when stratified by angiographic status), and Charlson co-morbidity index (except when stratified by Charlson co-morbidity index).
have been previously identified as the primary reason for improved short term survival of patients with acute myocardial infarction.24 The improvement found in our study paralleled the implementation of a national plan in Denmark in 1993 aimed at rapidly expanding the capacity for performing interventional cardiological procedures, including coronary angiography, PCI, and CABG. As a consequence of this initiative, the total number of coronary angiograms and of PCI or CABG performed in Denmark increased by 387% and 331%, respectively, during the 1992–2000 period. However, the proportion of patients undergoing revascularisation procedures during follow up did not change dramatically across the 1992, 1996, and 2000 patient cohorts. Thus, the increased capacity for interventional procedures in itself is not likely to explain the improvement in survival. At the same time, improvements in the effectiveness of the procedures, such as increased use of coronary stents during PCI procedures for preventing restenosis and in particular implementation of potent antithrombotic regimens, are likely to have been important. This is reinforced by our findings of a substantial improvement during the 1990s in survival among patients undergoing revascularisation during follow up.

Furthermore, use of cardiovascular drugs for secondary prevention appears to have increased among Danish patients with IHD during the 1990s.28–30 However, as shown in the EUROASPIRE (European action on secondary prevention through intervention to reduce events) I and II surveys, many patients with IHD still do not reach the recommended treatment goals and the proportion of patients who are either smokers or obese appears to be stable or even increasing.27 Moreover, the improvement in survival may not apply to all categories of patients with IHD. Long term survival after out of hospital cardiac arrest remains poor,28 and about 70% of all deaths caused by IHD occur unexpectedly and outside the hospital, often among people with undiagnosed IHD.28–30 Thus, there is clear potential for further improving the survival of patients with IHD in western populations.

In conclusion, we found a major improvement in the survival of a population based sample of Danish patients evaluated by coronary angiography for known or suspected IHD during the 1990s. The improvement appeared not to be explained by differences in available patient characteristics, including age, sex, indication (acute or elective), angiographic status, and Charlson co-morbidity index, or by the improvement in overall survival in the general population during the same period. Several factors, including a substantial increase in the use of coronary revascularisation and cardiovascular drugs for secondary prevention, may underlie the improvement.

Authors’ affiliations

S P Johnsen, L Pedersen, H T Sørensen, Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
J Videbaek, The Danish Heart Foundation, Copenhagen, Denmark
R Steffensen, Department of Cardiology, Hillerød Hospital, Hillerød, Denmark
R Videbaek, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
T Niemann, Department of Medicine, Herning Hospital, Herning, Denmark
T T Nielsen, Department of Cardiology, Skejby Hospital, Aarhus University Hospital, Aarhus, Denmark

Source of funding: Danish Heart Foundation

The study was approved by The Danish Data Protection Agency (J nr 2001-41-0903).

References